Please use this identifier to cite or link to this item:
|Title:||Intravenous thrombolysis for acute ischemic stroke in Asia||Authors:||Sharma, V.K.
|Keywords:||acute ischemic stroke
tissue plasminogen activator
|Issue Date:||Feb-2012||Citation:||Sharma, V.K., Ng, K.W.P., Venketasubramanian, N., Teoh, H.L., Chan, B.P.L. (2012-02). Intravenous thrombolysis for acute ischemic stroke in Asia. Expert Review of Neurotherapeutics 12 (2) : 209-217. ScholarBank@NUS Repository. https://doi.org/10.1586/ern.11.148||Abstract:||Data regarding thrombolysis for acute ischemic stroke in Asia are scarce and only a small percentage of patients are thrombolysed. Clinical trials that led to the recommended dose of intravenously administered tissue plasminogen activator (IV-tPA) included predominantly Caucasian patients. However, the single-arm case-controlled observational studies in Japanese patients suggested the clinical efficacy and safety of low-dose IV-tPA (0.6 mg/kg bodyweight; maximum 60 mg) comparable with standard dose (0.9 mg/kg bodyweight; maximum 90 mg). There has been no randomized clinical trial for determining the dose, efficacy or safety of IV-tPA in Asia. Accordingly, the dose of IV-tPA in Asia remains controversial. Reduced treatment cost, lower symptomatic intracerebral hemorrhage risk and comparable efficacy encouraged many Asian centers to adopt low-dose or even variable-dose IV-tPA regimens. We present the current status of thrombolysis for acute ischemic stroke in Asia. © 2012 Expert Reviews Ltd.||Source Title:||Expert Review of Neurotherapeutics||URI:||http://scholarbank.nus.edu.sg/handle/10635/125853||ISSN:||14737175||DOI:||10.1586/ern.11.148|
|Appears in Collections:||Staff Publications|
Show full item record
Files in This Item:
There are no files associated with this item.
checked on Jul 4, 2020
WEB OF SCIENCETM
checked on Jun 25, 2020
checked on Jun 26, 2020
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.